The protein content of caspase 3 was also shown to be elevated in myotubes treated with ESLD serum and leucine compared with NAFLD serum alone (173%, p = 0.03, d = 2.2). Here, CASP3 is linked to metabolic dysfunction-associated steatotic liver disease.